Publication | Open Access

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

MedicinePharmacologyPathologyImmune Checkpoint InhibitorBronchial NeoplasmIfct-1603 TrialCancer TreatmentSecond-line TherapyOncologyRadiation OncologyLung Cancer